Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. The company engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company offers its products for various therapeutic categories, such as anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastrointestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain and analgesics, respiratory, and vitamins, minerals, and nutrients; and contract development services. The company was incorporated in 1978 and is headquartered in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma Industrial Pte. Ltd.

Revenue projections:

Revenue projections for GLAND
Revenue projections for GLAND

Investors are expected to be cautious with GLAND, as its revenues are projected to fall compared to last year. A decline in revenue often results in a negative impact on profitability, prompting concerns about the company's financial stability and making investors more conservative in their approach.

Financial Ratios:

currentRatio 0.00000
forwardPE 25.29622
debtToEquity 3.16100
earningsGrowth 0.27800
revenueGrowth 0.22500
grossMargins 0.58863
operatingMargins 0.19302
trailingEps 51.37000
forwardEps 72.01471

GLAND's Forward PE is in a strong range, indicating that its stock price compares well with its earnings. The stock is not considered overpriced, leaving ample room for growth and making it a promising option for investors looking for value and future returns.
Gland Pharma Limited's positive earnings and revenue growth signal that the company is expected to expand its business. This healthy financial trend reflects an optimistic outlook, suggesting continued growth in both sales and profits for Gland Pharma Limited.
Gland Pharma Limited's forward EPS is higher than its trailing EPS, suggesting the company is expected to improve its profitability this financial year. This reflects growing confidence in Gland Pharma Limited's earnings potential, with forecasts indicating better financial performance than in the prior year.

Price projections:

Price projections for GLAND
Price projections for GLAND

The price of Gland Pharma Limited has remained consistently close to the lower limit of projections. This ongoing pattern raises concerns about the stock's performance and may reflect market hesitance regarding the company's growth prospects.

Insider Transactions:

Insider Transactions for GLAND
Insider Transactions for GLAND


GLAND stock was sold in 5 transactions, with market price at 1913.4599853515624.No sell transactions were carried out during the period under review.With more buys than sells around GLAND's current price, there seems to be increased confidence among investors. This shift may indicate a favorable outlook, as the buying behavior suggests optimism for the stock's future growth or resilience.

Recommendation changes over time:

Recommendations trend for GLAND
Recommendations trend for GLAND


The analysts' recent buy bias for GLAND indicates strong confidence in the stock's future performance. This could encourage more investors to view GLAND as a worthwhile investment, positioning the company as a top choice for those seeking financial security and long-term growth opportunities.